Abstract
Despite extended, aggressive use of conventional antibiotics, drug treatment of bone infections frequently fails as a combined result of the widespread of drug-resistant bacteria, poor accessibility of many antimicrobials to the deeper portion of the bones, the ease of biofilm formation on the bone surface, and high risk of drug toxicity. Emerging therapeutic nanotechnology offers potential solutions to these issues. In recent years, a number of nanoantimicrobials, i.e. nanoscale devices with intrinsic antibacterial activities or capacity for delivering antibiotics, have been developed for the treatment and prevention of bone infections. These nanoantimicrobials can be designed to have controlled and sustained drug release kinetics, surface-modifications for bone or bacteria targeting, and increased affinity for biofilms. Given the potential value of nanoantimicrobials, clinical application of nanoantimicrobials for bone infection treatment remains scant when compared with the number of ongoing research. It is, therefore, a good time to carefully examine this promising yet relatively uncharted area. This review will extensively discuss the development and state of the art of different classes of nanoantimicrobials for bone infections with emphasis on the treatment aspect and identify the factors that prevent the clinical translation of nanoantimicrobial therapy from bench to bedside.
Keywords: Osteomyelitis, antibiotics, nanotechnology, nanoantimicrobial, drug delivery, targeted delivery, bone.
Current Drug Delivery
Title:Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art
Volume: 15 Issue: 7
Author(s): Pengbo Guo, Hui-Yi Xue*Ho-Lun Wong*
Affiliation:
- Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140,United States
- Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140,United States
Keywords: Osteomyelitis, antibiotics, nanotechnology, nanoantimicrobial, drug delivery, targeted delivery, bone.
Abstract: Despite extended, aggressive use of conventional antibiotics, drug treatment of bone infections frequently fails as a combined result of the widespread of drug-resistant bacteria, poor accessibility of many antimicrobials to the deeper portion of the bones, the ease of biofilm formation on the bone surface, and high risk of drug toxicity. Emerging therapeutic nanotechnology offers potential solutions to these issues. In recent years, a number of nanoantimicrobials, i.e. nanoscale devices with intrinsic antibacterial activities or capacity for delivering antibiotics, have been developed for the treatment and prevention of bone infections. These nanoantimicrobials can be designed to have controlled and sustained drug release kinetics, surface-modifications for bone or bacteria targeting, and increased affinity for biofilms. Given the potential value of nanoantimicrobials, clinical application of nanoantimicrobials for bone infection treatment remains scant when compared with the number of ongoing research. It is, therefore, a good time to carefully examine this promising yet relatively uncharted area. This review will extensively discuss the development and state of the art of different classes of nanoantimicrobials for bone infections with emphasis on the treatment aspect and identify the factors that prevent the clinical translation of nanoantimicrobial therapy from bench to bedside.
Export Options
About this article
Cite this article as:
Guo Pengbo , Xue Hui-Yi *, Wong Ho-Lun*, Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art, Current Drug Delivery 2018; 15 (7) . https://dx.doi.org/10.2174/1567201815666180228162949
| DOI https://dx.doi.org/10.2174/1567201815666180228162949 |
Print ISSN 1567-2018 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances in Drug Delivery for Modern Dentistry
This special issue of Current Drug Delivery is dedicated to exploring the cutting-edge integration of drug delivery technologies within the field of dentistry. As oral diseases remain among the most prevalent health challenges worldwide, there is an urgent need for innovative, effective, and patient-friendly therapeutic approaches. This issue highlights how ...read more
Advances of Natural Products, Bio-Actives and Novel Drug Delivery System Against Emerging Viral Infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity, and high bioavailability. The most suitable ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Exosome-Based Drug Delivery for Regenerative Medicine
Exosome-based drug delivery is emerging as a transformative technology in regenerative medicine due to exosomes' natural ability to mediate intercellular communication and carry bioactive molecules like proteins, lipids, and nucleic acids. This thematic issue focuses on exosomes as nanocarriers for therapeutic delivery, harnessing their potential to enhance tissue repair, immune ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methotrexate overdose in clinical practice
Current Drug Metabolism “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry X-Ray Versus Magnetic Resonance Imaging in Diabetic Foot Osteomyelitis: A Clinical Comparison
Current Diabetes Reviews Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Immunoinformatics and Reverse Vaccinology Driven Predication of a Multi-epitope Vaccine against <i>Borrelia burgdorferi</i> and Validation through <i>in silico</i> Cloning and Immune Simulation
Current Pharmaceutical Design An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging
CNS & Neurological Disorders - Drug Targets Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Chest Pain in Children
Current Pediatric Reviews Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets





